• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    BillionToOne Provides Guidance for 2026

    1/12/26 8:05:00 AM ET
    $BLLN
    Medical Specialities
    Health Care
    Get the next $BLLN alert in real time by email

    MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reiterated the full year 2025 guidance of $293 million to $299 million with positive GAAP operating income and initiated the full year 2026 guidance.

    Full Year 2026 Guidance

    • Full year 2026 total revenue of $415 million to $430 million, representing growth of 40% to 45% compared to the midpoint of the full year 2025 guidance range.
    • Positive GAAP operating income for the full year 2026.

    "As we look ahead to 2026, we are excited by the opportunity to further scale our differentiated platform built on innovative science and disciplined execution," said Dr. Oguzhan Atay, Co-founder and CEO of BillionToOne. "With a clear roadmap and focus on solving meaningful clinical challenges, we believe we are well positioned to deepen our impact on healthcare, while delivering a durable, high-quality growth profile this year."

    About BillionToOne

    Headquartered in Menlo Park, California, BillionToOne is a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all. The company's patented Quantitative Counting Templates™ (QCT™) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single-molecule level. For more information, visit www.billiontoone.com.

    Forward-Looking Statements

    This press release contains certain forward-looking statements within the meaning of federal securities laws. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements in this press release include, but are not limited to, statements regarding estimated revenue, income and other financial information for the full years of 2025 and 2026.  These statements are based on management's current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, some of which are beyond BillionToOne's control. These and additional risks and uncertainties that could affect BillionToOne's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. These risks and uncertainties include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in BillionToOne's most recently filed quarterly report on Form 10Q and other filings we make with the Securities and Exchange Commission from time to time. The forward-looking statements in this press release are based on information available to BillionToOne as of the date hereof, and BillionToOne disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing BillionToOne's views as of any date subsequent to the date of this press release.

    Investor Contact

    [email protected]

    Media Contact 

    [email protected]



    Primary Logo

    Get the next $BLLN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLLN

    DatePrice TargetRatingAnalyst
    1/6/2026$120.00Buy
    Guggenheim
    12/1/2025Outperform
    William Blair
    12/1/2025$117.00Hold
    Jefferies
    12/1/2025$150.00Overweight
    Analyst
    12/1/2025$150.00Overweight
    Piper Sandler
    12/1/2025$145.00Buy
    Stifel
    12/1/2025$110.00Equal Weight
    Wells Fargo
    12/1/2025$160.00Buy
    BTIG Research
    More analyst ratings

    $BLLN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Humming Bird Ventures Management Nv disposed of 7,887,187 shares, acquired 7,887,187 shares and converted options into 7,707,188 shares (SEC Form 4)

    4 - BillionToOne, Inc. (0002070849) (Issuer)

    1/20/26 7:27:56 PM ET
    $BLLN
    Medical Specialities
    Health Care

    New insider Humming Bird Ventures Management Nv claimed ownership of 179,999 shares (SEC Form 3)

    3 - BillionToOne, Inc. (0002070849) (Issuer)

    1/20/26 7:25:53 PM ET
    $BLLN
    Medical Specialities
    Health Care

    Director Pagano Anthony was granted 4,896 shares (SEC Form 4)

    4 - BillionToOne, Inc. (0002070849) (Issuer)

    1/5/26 8:52:49 PM ET
    $BLLN
    Medical Specialities
    Health Care

    $BLLN
    SEC Filings

    View All

    SEC Form DEFA14A filed by BillionToOne Inc.

    DEFA14A - BillionToOne, Inc. (0002070849) (Filer)

    4/21/26 4:26:02 PM ET
    $BLLN
    Medical Specialities
    Health Care

    SEC Form DEF 14A filed by BillionToOne Inc.

    DEF 14A - BillionToOne, Inc. (0002070849) (Filer)

    4/21/26 4:25:37 PM ET
    $BLLN
    Medical Specialities
    Health Care

    SEC Form 10-K filed by BillionToOne Inc.

    10-K - BillionToOne, Inc. (0002070849) (Filer)

    3/11/26 4:55:45 PM ET
    $BLLN
    Medical Specialities
    Health Care

    $BLLN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BillionToOne to Report First Quarter 2026 Financial Results on May 6, 2026

    MENLO PARK, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the first quarter ended March 31, 2026 after the market close on Wednesday, May 6, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day. Analysts planning to participate in the conference call should register here before the 1:30pm Pacific Time / 4:30pm Eastern Time start. A live and archived webcast for interested l

    4/15/26 8:05:00 AM ET
    $BLLN
    Medical Specialities
    Health Care

    BillionToOne Appoints Dr. Allen Chen as Vice President of Medical Affairs and Clinical Development, Oncology

    Renowned physician executive and clinician-scientist joins BillionToOne to advance oncology medical strategyMENLO PARK, Calif., April 2, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company focused on making highly accurate testing accessible to all, today announced the appointment of Allen Chen, MD, MBA, FASTRO, FACHE, as Vice President of Medical Affairs and Clinical Development, Oncology. This new appointment reflects BillionToOne's continued commitment to building world-class oncology medical leadership as the company grows its Northstar liquid biopsy portfolio.

    4/2/26 9:00:00 AM ET
    $BLLN
    Medical Specialities
    Health Care

    BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance

    MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the fourth quarter and full year ended December 31, 2025 and raised guidance for full year 2026. Financial Highlights: Total revenue of $96.1 million in the fourth quarter of 2025, compared to $45.1 million in the fourth quarter of 2024, an increase of 113%.Prenatal clinical testing revenue was $86.1 million in the fourth quarter of 2025, an increase of 99% from the fourth quarter 2024.Oncology clinical testing revenue was $9.1 milli

    3/4/26 4:05:00 PM ET
    $BLLN
    Medical Specialities
    Health Care

    $BLLN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on BillionToOne with a new price target

    Guggenheim initiated coverage of BillionToOne with a rating of Buy and set a new price target of $120.00

    1/6/26 8:54:21 AM ET
    $BLLN
    Medical Specialities
    Health Care

    William Blair initiated coverage on BillionToOne

    William Blair initiated coverage of BillionToOne with a rating of Outperform

    12/1/25 8:36:56 AM ET
    $BLLN
    Medical Specialities
    Health Care

    Jefferies initiated coverage on BillionToOne with a new price target

    Jefferies initiated coverage of BillionToOne with a rating of Hold and set a new price target of $117.00

    12/1/25 8:27:06 AM ET
    $BLLN
    Medical Specialities
    Health Care

    $BLLN
    Leadership Updates

    Live Leadership Updates

    View All

    BillionToOne Appoints Dr. Allen Chen as Vice President of Medical Affairs and Clinical Development, Oncology

    Renowned physician executive and clinician-scientist joins BillionToOne to advance oncology medical strategyMENLO PARK, Calif., April 2, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company focused on making highly accurate testing accessible to all, today announced the appointment of Allen Chen, MD, MBA, FASTRO, FACHE, as Vice President of Medical Affairs and Clinical Development, Oncology. This new appointment reflects BillionToOne's continued commitment to building world-class oncology medical leadership as the company grows its Northstar liquid biopsy portfolio.

    4/2/26 9:00:00 AM ET
    $BLLN
    Medical Specialities
    Health Care

    BillionToOne Appoints Anthony Pagano to Board of Directors as Audit Committee Chair

    MENLO PARK, Calif., Dec. 9, 2025 /PRNewswire/ – BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the appointment of Anthony Pagano to its Board of Directors, effective January 1, 2026. Mr. Pagano will also serve as Chair of the Audit Committee. Mr. Pagano is currently Chief Financial Officer and Executive Vice President of Genmab, a leading international biotechnology company, a position he has held since March 2020. He joined Genmab in December 200

    12/9/25 4:07:00 PM ET
    $BLLN
    Medical Specialities
    Health Care

    $BLLN
    Financials

    Live finance-specific insights

    View All

    BillionToOne to Report First Quarter 2026 Financial Results on May 6, 2026

    MENLO PARK, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the first quarter ended March 31, 2026 after the market close on Wednesday, May 6, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day. Analysts planning to participate in the conference call should register here before the 1:30pm Pacific Time / 4:30pm Eastern Time start. A live and archived webcast for interested l

    4/15/26 8:05:00 AM ET
    $BLLN
    Medical Specialities
    Health Care

    BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance

    MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the fourth quarter and full year ended December 31, 2025 and raised guidance for full year 2026. Financial Highlights: Total revenue of $96.1 million in the fourth quarter of 2025, compared to $45.1 million in the fourth quarter of 2024, an increase of 113%.Prenatal clinical testing revenue was $86.1 million in the fourth quarter of 2025, an increase of 99% from the fourth quarter 2024.Oncology clinical testing revenue was $9.1 milli

    3/4/26 4:05:00 PM ET
    $BLLN
    Medical Specialities
    Health Care

    BillionToOne to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

    MENLO PARK, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for fourth quarter and full year ended December 31, 2025 after the market close on Wednesday, March 4, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day. To participate in the conference call, please register here before the 1:30pm Pacific Time / 4:30pm Eastern Time start. A live and archived webcast will be available

    2/17/26 8:05:00 AM ET
    $BLLN
    Medical Specialities
    Health Care